Next generation nasal device is capable of delivering an accurate single dose of a wide range of therapeutic agents
Bespak has announced the commercial availability of UniDose DP - an innovative dry powder nasal device capable of delivering an accurate single dose of a wide range of therapeutic agents. Designed to provide a consistent, reproducible delivery of powder, Unidose DP offers a more than 90% delivery efficiency of the metered dose in a single actuation.
Suitable for commercial development by pharmaceutical and generics companies, it is an ideal alternative delivery mechanism for the accurate administration of a range of formulations including proteins, peptides and vaccines.
